Regencell (RGC) Total Debt to Equity Ratio

Regencell Bioscience (RGC) business relies on a narrow specialization in neuroscience utilizing Eastern medicine methods, which creates high binary risks. The company's strategy is based on capturing the autism and ADHD therapy segment through a series of large-scale tests of its own formulas. This chart illustrates the market value of the asset with the 0.02 metric, highlighting financial vulnerability due to a lack of sales and dependence on external investments.

Regencell Bioscience is developing a unique niche in biomedicine, leveraging a stable geopolitical status to conduct research without hindrance. An analysis of the total debt-to-equity ratio allows for an assessment of the proportion of borrowed funds within the asset structure relative to equity, determining the issuer's degree of financial autonomy. Low values for this indicator confirm the business's high resilience to external shocks, minimizing default risks during the scaling of developments.